Deal Watch: Exelixis Teams With Ipsen For Ex-US Commercialization Of RCC Candidate
Executive Summary
Onxeo acquires signal-interfering DNA repair technology for its orphan oncology focus. Sanofi returns auto-injector product to kaleo after product recall.
You may also be interested in...
BMS' Opdivo Gets CHMP Backing For Expanded European Label
Use for previously treated advanced renal cell carcinoma in adults as well as previously treated metastatic non-squamous non-small cell lung cancer, regardless of PD-L1 expression, is recommended by EMA Committee for Medicinal Products for Human Use.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.